Sonoma Pharmaceuticals, Inc. engages in identifying, developing, and commercializing therapies for chronic skin conditions. The company offers solutions in dermatology, animal healthcare, and advanced tissue care product areas. Its products target skin diseases including acne, atopic dermatitis, scarring, infections, itch, pain, and harmful inflammatory responses. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Petaluma, CA.
Total revenues for the year ended March 31, 2019 of $18,970,000 increased by $2,312,000, or 14%, as compared to $16,658,000 for the year ended March 31, 2018. Product revenues for the year ended March 31, 2019 of $17,881,000 increased by $2,218,000, or 14%, as compared to $15,663,000 for the year ended March 31, 2018. This increase was primarily the result of growth in product revenue of $668,000, or 8%, in the United States, growth in product revenue of $955,000, or 32%, in Latin America, and growth of product revenue of $595,000, or 14%, in Europe and Rest of World.